Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biocon Ltd. Capital/Financing Update 2025

Jun 19, 2025

61176_rns_2025-06-19_ada5c28a-6621-4810-bdc3-89df710c76a0.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [132 x 53] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/EA/2025-26/43

June 19, 2025

To
The Manager,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street,Mumbai – 400 001
To
The Manager,
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex
Mumbai – 400 050
Scrip Code - 532523 Scrip Symbol - BIOCON

Dear Sir/ Madam,

Subject: Qualified Institutions Placement of equity shares of face value ₹ 5 each (“Equity Shares”) (such placement, the “Issue”) by Biocon Limited (the “Company”) under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and Sections 42, 23(1)(b) and 62(1)(c) of the Companies Act, 2013, as amended.

In furtherance to our letter dated June 16, 2025, informing you about the opening of the issue and the floor price for the Issue, we wish to inform you that the Fund Raising Committee at its meeting held today i.e. Thursday, June 19, 2025, has, inter alia, passed the following resolutions:

  • a. Approved the closure of the Issue today (i.e. Thursday, June 19, 2025) pursuant to the receipt of application forms and the funds in the escrow account from the eligible qualified institutional buyers in accordance with the terms of the Issue;

  • b. Determined and approved, in accordance with the SEBI ICDR Regulations, the allocation of 136,363,635 Equity Shares at an Issue price of 330 per Equity Share, which is at a discount of ₹ 10.20 per Equity Share i.e. 3 % to the floor price of ₹ 340.20 per Equity Share, (including a premium of ₹ 325 per Equity Share) upon the closure of the Issue, according to the formula prescribed under Regulation 176(1) of the SEBI ICDR Regulations, as amended, for the Equity Shares to be allotted to the eligible qualified institutional buyers in the Issue; and

  • c. Approved and finalized the confirmation of allocation note to be sent to eligible qualified institutional buyers, intimating them of the allocation of Equity Shares pursuant to the Issue.

The meeting of the Fund Raising Committee commenced at 7:30 PM and concluded at 7:45 PM.

The Issue was opened on Monday, June 16, 2025 and the same was intimated to you pursuant to our letter dated June 16, 2025.

==> picture [132 x 53] intentionally omitted <==

We request you to kindly take this on records and treat the same as compliance under Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations Disclosure Requirements) Regulations, 2015, as amended.

Copy of this intimation is being also made available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

Digitally signed SIDDHART by SIDDHARTH MITTAL H MITTAL Date: 2025.06.19 19:46:36 +05'30'


Siddharth Mittal Managing Director & CEO DIN: 03230757